

Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

Mouse Anti-CD226 Monoclonal Antibody, Unconjugated, Clone DX11

RRID:AB_397327

Type: Antibody

Proper Citation

BD Biosciences Cat# 559786, RRID:AB_397327

Antibody Information

URL: http://antibodyregistry.org/AB_397327

Proper Citation: BD Biosciences Cat# 559786, RRID:AB_397327

Target Antigen: CD226

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry, Functional assay

Antibody Name: Mouse Anti-CD226 Monoclonal Antibody, Unconjugated, Clone DX11

Description: This monoclonal targets CD226

Target Organism: human

Clone ID: DX11

Antibody ID: AB_397327

Vendor: BD Biosciences

Catalog Number: 559786

Record Creation Time: 20250820T033518+0000

Record Last Update: 20250820T163856+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-CD226 Monoclonal Antibody, Unconjugated, Clone DX11.

No alerts have been found for Mouse Anti-CD226 Monoclonal Antibody, Unconjugated, Clone DX11.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Li YR, et al. (2025) Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. Nature protocols, 20(5), 1352.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (New York, N.Y.), 100804.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience, 26(10), 107952.

van Vliet AA, et al. (2023) Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells. iScience, 26(7), 107078.

Li YR, et al. (2022) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. iScience, 25(9), 104859.

Li YR, et al. (2021) Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell reports. Medicine, 2(11), 100449.